DE602005014789D1 - Phosphorylierte vimentin als marker für die aggressivität und /oder invasivität von tumoren - Google Patents

Phosphorylierte vimentin als marker für die aggressivität und /oder invasivität von tumoren

Info

Publication number
DE602005014789D1
DE602005014789D1 DE602005014789T DE602005014789T DE602005014789D1 DE 602005014789 D1 DE602005014789 D1 DE 602005014789D1 DE 602005014789 T DE602005014789 T DE 602005014789T DE 602005014789 T DE602005014789 T DE 602005014789T DE 602005014789 D1 DE602005014789 D1 DE 602005014789D1
Authority
DE
Germany
Prior art keywords
aggressiveness
invasiveness
marker
vimentin
invasivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005014789T
Other languages
English (en)
Inventor
Ali Bouamrani
Emmanuel Gay
Jean-Paul Issartel
Francois Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of DE602005014789D1 publication Critical patent/DE602005014789D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE602005014789T 2004-09-17 2005-09-15 Phosphorylierte vimentin als marker für die aggressivität und /oder invasivität von tumoren Active DE602005014789D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0409857A FR2875601B1 (fr) 2004-09-17 2004-09-17 Vimentine phosphorylee comme marqueur de l'agressivite et/ou l'invasivite des tumeurs
PCT/EP2005/054598 WO2006030023A1 (fr) 2004-09-17 2005-09-15 Vimentine phosphorylée comme marqueur de l'agressivité et/ou l'invasivité des tumeurs

Publications (1)

Publication Number Publication Date
DE602005014789D1 true DE602005014789D1 (de) 2009-07-16

Family

ID=34953933

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005014789T Active DE602005014789D1 (de) 2004-09-17 2005-09-15 Phosphorylierte vimentin als marker für die aggressivität und /oder invasivität von tumoren

Country Status (7)

Country Link
US (1) US20070265185A1 (de)
EP (1) EP1789802B1 (de)
AT (1) ATE433111T1 (de)
DE (1) DE602005014789D1 (de)
ES (1) ES2326987T3 (de)
FR (1) FR2875601B1 (de)
WO (1) WO2006030023A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374450T3 (es) * 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
JP5240739B2 (ja) * 2007-04-13 2013-07-17 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
EP2208066A2 (de) * 2007-10-03 2010-07-21 OSI Pharmaceuticals, Inc. Biologische marker zur vorhersage der antikrebs-antwort auf insulinähnlicher-wachstumsfaktor-1-rezeptorkinase-inhibitoren
AU2008307634A1 (en) * 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2400990A2 (de) * 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In-situ-verfahren zur überwachung des emt-status von tumorzellen in vivo
US20110217309A1 (en) * 2010-03-03 2011-09-08 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013151314A1 (ko) * 2012-04-03 2013-10-10 연세대학교 산학협력단 비멘틴을 포함하는 탈모 억제 또는 발모 촉진용 조성물
JP2016512197A (ja) 2013-03-05 2016-04-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 間葉及び上皮間葉形質転換循環腫瘍細胞のための特異的検出ツール
US20170307615A1 (en) * 2014-09-24 2017-10-26 Geisinger Health System Immunohistochemistry Quality Management Program Using Cultured Cell Lines for Tissue Microarray (TMA) Blocks
WO2017100789A1 (en) * 2015-12-11 2017-06-15 Expression Pathology, Inc. Srm/mrm assays
CN113564172A (zh) * 2021-06-30 2021-10-29 优葆优保健康科技(宁波)有限公司 一种液体活检肿瘤细胞dna适配体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3829226B2 (ja) * 1999-07-07 2006-10-04 独立行政法人理化学研究所 ビメンチンの切断産物に対する抗体
US7910314B2 (en) * 2002-03-01 2011-03-22 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
CA2478924A1 (en) * 2002-03-14 2003-09-18 Qlt Inc. Cancer associated araf1 protein kinase and its uses

Also Published As

Publication number Publication date
EP1789802A1 (de) 2007-05-30
ES2326987T3 (es) 2009-10-22
FR2875601A1 (fr) 2006-03-24
US20070265185A1 (en) 2007-11-15
WO2006030023A1 (fr) 2006-03-23
EP1789802B1 (de) 2009-06-03
FR2875601B1 (fr) 2007-04-13
ATE433111T1 (de) 2009-06-15

Similar Documents

Publication Publication Date Title
DE602005014789D1 (de) Phosphorylierte vimentin als marker für die aggressivität und /oder invasivität von tumoren
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
WO2006017150A3 (en) Identification of markers in lung and breast cancer
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2004031411A3 (en) Genes and polypeptides relating to human pancreatic cancers
EA200601433A1 (ru) Способы и композиции для лечения опухолей и метастазирования
TW200626900A (en) Wnt proteins and detection and treatment of cancer
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
HK1101348A1 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
WO2004056874A3 (en) Neuropilin-1 inhibitors
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2006095086A3 (fr) Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
DE50311312D1 (de) Verfahren zum untersuchen von körperflüssikeiten auf krebszellen sowie entsprechende analysekits
EP1377596A4 (de) Ttk in der diagnose und als therapeutisches target bei krebs
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
MXPA04003931A (es) Pronostico de cancer de mama.
DE60221115D1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
WO2004003166A3 (en) Antibodies and uses thereof
WO2004101762A3 (en) Detection and treatment of cancers of the colon
ATE466958T1 (de) Klassifizierung von kolonkrebs
DE60323677D1 (de) Verfahren zur bestimmung des wiederauftretens von prostata krebs
ATE486964T1 (de) Molekulares verfahren zur diagnose von prostatakrebs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition